Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells

Journal of the National Cancer Institute

Volumn 88, Issue 13, 1996, Pages 908-917

  Robertson, Cary N ^a   Roberson, Kathryn M ^a   Padilla, George M ^a   O'Brien, E Timothy ^b   Cook, J Michael ^b   Kim, Choung Soo ^a   Fine, Robert L ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ANDROGEN; COLCHICINE; DIETHYLSTILBESTROL; DNA FRAGMENT; ESTRADIOL; ESTROGEN RECEPTOR; FOSFESTROL; PHALLOIDIN; PROPIDIUM IODIDE; TUBULIN;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GROWTH INHIBITION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; DIETHYLSTILBESTROL; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, AGAR GEL; ESTRADIOL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICROSCOPY, ULTRAVIOLET; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 0029957862     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.13.908     Document Type: Article

References (54)

1. Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1989;34:134-8.
2. Abramson FP, Miller HC Jr. Bioavailability, distribution and pharmaco-kinetics of diethylstilbestrol produced from stilphostrol. J Urol 1982;128: 1336-9.
3. Flocks RH, Marberger H, Begley BJ, Hans M, Prendergast LJ. Prostatic carcinoma: treatment of advanced cases with intravenous diethylstilbestrol diphosphate. J Urol 1955;74:549-51.
4. Band PR, Banerjee TK, Patwardhan VC, Eid TC. High-dose diethylstilbestrol diphosphate therapy of prostatic cancer after failure of standard doses of estrogens. Can Med Assoc J 1973;109:697-9.
5. Colapinto V, Aberhart C. Clinical trial of massive stilbestrol diophosphate therapy in advanced carcinoma of the prostate. Br J Urol 1961;33:171-7.
6. Droz JP, De Smedt E, Kattan J, Keuppens F, Khoury S, Mahler C, et al. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate 1994;24:62-6.
7. Hawtrey CE, Welch MJ Jr, Schmidt JD, Culp DA, Flocks RH. Paraplegia and paraparesis due to prostate cancer. Use of intravenous diethylstil-bestrol diphosphate. Urology 1974;4:431-4.
8. Schulz P, Link TA, Chaudhuri L, Fittler F. Role of the mitochondrial bcl-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 1990;50:5008-12.
9. Paulson DF. Carcinoma of the prostate: the therapeutic dilemma. Annu Rev Med 1984;35:341-72.
10. Brehmer B, Marquardt H, Madsen PO. Growth and hormonal response of cells derived from carcinoma and hyperplasia of the prostate in monolayer cell culture. A possible in vitro model for clinical chemotherapy. J Urol 1972;108:890-6.
11. McEnery MW, Hullihen J, Pedersen PL. F0 proton channel of rat liver mitochondria. Rapid purification of a functional complex and a study of its interaction with the unique probe diethylstilbestrol. J Biol Chem 1989; 264:12029-36.
12. Aizu-Yokota E, Ichinoseki K, Sato Y. Microtubule disruption induced by estradiol in estrogen receptor-positive and -negative human breast cancer cell lines. Carcinogenesis 1994;15:1875-9.
13. Hartley-Asp B, Deinum J, Wallin M. Diethylstilbestrol induces melaphase arrest and inhibits microtuble assembly. Mutat Res 1985;143:231-5.
14. Sawada M, Ishidate M Jr. Colchicine-like effect of diethylstilbestrol (DES) on mammalian cells in vitro. Mutat Res 1978;57:175-82.
15. Tsutsui T, Maizumi H, McLachlan JA, Barrett JC. Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosomal mechanism in carcinogenesis. Cancer Res 1983;43:3814-21.
16. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 1993;53:4573-81.
17. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10:1754-61.
18. Sargent LM, Dragan YP, Bahnub N, Wiley JE, Sattler CA, Schroeder P. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 1984;54:3357-60.
19. Konishi N, Nakaoka S, Hiasa Y, Kitahori Y, Ohshima M, Samma S, et al. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and relationship to efficacy of endocrine therapy. Oncology 1993;50:259-63.
20. Ware JL, Paulson DF, Mickey GH, Webb KS. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 1982;128:1064-7.
21. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-81.
22. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
23. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43: 1809-18.
24. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
25. Borner MM, Schneider E, Pirnia F, Sartor O, Trepel JB, Myers CE. The detergent Triton X-100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte-induced apoptosis. FEBS Lett 1994;353:129-32.
26. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-6.
27. Borisy GG, Taylor EW. The mechanism of colchicine action. Colchicine binding to sea urchin eggs and the mitotic apparatus. J Cell Biol 1967; 34:535-48.
28. Inoue S. Effects of colchicine on the microscopic and submicroscopic structure of the mitotic spindle. Exp Cell 1952;2:305-14.
29. Eklov S, Nilsson S, Larson A, Bjork P, Hartley-Asp B. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992;20:43-50.
30. Sharp DC, Parry JM. Diethylstilbestrol: the binding and effects of diethylstilbestrol upon the polymerization and depolymerization of purified microtubule protein in vitro. Carcinogenesis 1985;6:865-71.
31. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984;132: 38-42.
32. McConkey DJ, Hartzell P, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation kills immature thymocytes. FASEB J 1989;3:1843-9.
33. McConkey DJ, Nicotera P, Hartzell P, Belloma G, Wyllie AH, Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys 1989;269: 365-70.
34. McConkey DJ, Hartzell P, Orrenius S. Rapid turnover of endogenous endonuclease activity in thymocytes: effects of inhibitors of macromolecular synthesis. Arch Biochem Biophys 1989;278:284-7.
35. McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol 1990;145:1227-30.
36. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
37. Orrenius S, McConkey DJ, Bellomo G, Nicotera P. Role of Ca2+ in toxic cell killing. Trends Pharmacol Sci 1989;10:281-5.
38. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 1995;55:944-8.
39. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994;218:314-9.
40. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-62.
41. Montpetit ML, Lawless KR, Tenniswood M. Androgen-repressed messages in the rat ventral prostate. Prostate 1986;8:25-36.
42. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
43. Russo P, Warner JA, Huryk R, Perez G, Heston WD. TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. Prostate 1994;24:237-43.
44. Danford N, Parry JM. Abnormal cell division in cultured human fibroblasts after exposure to diethylstilbestrol. Mutat Res 1982;103:379-83.
45. Szende B, Romics I, Vass L. Apoptosis in prostate cancer after hormonal treatment [letter]. Lancet 1993;342:1422.
46. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992;13:795-808.
47. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994;54:4952-7.
48. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993;53:3186-92.
49. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55.
50. Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52:1823-9.
51. Booher R, Beach D. Interaction between cdc13+ and cdc2+ in the control of mitosis in fission yeast; dissociation of the G1 and G2 roles of the cdc2+ protein kinase. EMBO J 1987;6:3441-7.
52. Pines J, Hunter T. P34/cdc2: the S and M kinase? New Biol 1990;2:389-401.
53. Gong J, Traganos F, Darzynkiewicz Z. Simultaneous analysis of cell cycle kinetics at two different DNA ploidy levels based on DNA content and cyclin B measurements. Cancer Res 1993;53:5096-9.
54. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, et al. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 1993;268:8298-308.